<?xml version='1.0' encoding='utf-8'?>
<document id="25975423"><sentence text="Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial."><entity charOffset="36-46" id="DDI-PubMed.25975423.s1.e0" text="etravirine" /><entity charOffset="50-61" id="DDI-PubMed.25975423.s1.e1" text="rilpivirine" /><entity charOffset="66-76" id="DDI-PubMed.25975423.s1.e2" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.25975423.s1.e0" e2="DDI-PubMed.25975423.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25975423.s1.e0" e2="DDI-PubMed.25975423.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25975423.s1.e0" e2="DDI-PubMed.25975423.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25975423.s1.e1" e2="DDI-PubMed.25975423.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25975423.s1.e1" e2="DDI-PubMed.25975423.s1.e2" /></sentence><sentence text="Coinfection with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) may require treatment with an HIV non-nucleoside reverse transcriptase inhibitor (NNRTI), for example, rilpivirine or etravirine, and an HCV direct-acting antiviral drug such as telaprevir"><entity charOffset="183-194" id="DDI-PubMed.25975423.s2.e0" text="rilpivirine" /><entity charOffset="198-208" id="DDI-PubMed.25975423.s2.e1" text="etravirine" /><entity charOffset="258-268" id="DDI-PubMed.25975423.s2.e2" text="telaprevir" /><pair ddi="false" e1="DDI-PubMed.25975423.s2.e0" e2="DDI-PubMed.25975423.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25975423.s2.e0" e2="DDI-PubMed.25975423.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25975423.s2.e0" e2="DDI-PubMed.25975423.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25975423.s2.e1" e2="DDI-PubMed.25975423.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25975423.s2.e1" e2="DDI-PubMed.25975423.s2.e2" /></sentence><sentence text=" In a two-panel, two-way, crossover study, healthy volunteers were randomized to receive etravirine 200 mg twice daily ± telaprevir 750 mg every 8 hours or rilpivirine 25 mg once daily ± telaprevir 750 mg every 8 hours"><entity charOffset="89-99" id="DDI-PubMed.25975423.s3.e0" text="etravirine" /><entity charOffset="156-167" id="DDI-PubMed.25975423.s3.e1" text="rilpivirine" /><pair ddi="false" e1="DDI-PubMed.25975423.s3.e0" e2="DDI-PubMed.25975423.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25975423.s3.e0" e2="DDI-PubMed.25975423.s3.e1" /></sentence><sentence text=" Pharmacokinetic assessments were conducted for each drug at steady-state when given alone and when coadministered; statistical analyses were least-square means with 90% confidence intervals" /><sentence text=" Telaprevir minimum plasma concentration (Cmin), maximum plasma concentration (Cmax), and area under the concentration-time curve (AUC) decreased 25%, 10%, and 16%, respectively, when coadministered with etravirine and 11%, 3%, and 5%, respectively, when coadministered with rilpivirine"><entity charOffset="1-11" id="DDI-PubMed.25975423.s5.e0" text="Telaprevir" /><entity charOffset="204-214" id="DDI-PubMed.25975423.s5.e1" text="etravirine" /><entity charOffset="275-286" id="DDI-PubMed.25975423.s5.e2" text="rilpivirine" /><pair ddi="false" e1="DDI-PubMed.25975423.s5.e0" e2="DDI-PubMed.25975423.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25975423.s5.e0" e2="DDI-PubMed.25975423.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25975423.s5.e0" e2="DDI-PubMed.25975423.s5.e2" /><pair ddi="false" e1="DDI-PubMed.25975423.s5.e1" e2="DDI-PubMed.25975423.s5.e1" /><pair ddi="false" e1="DDI-PubMed.25975423.s5.e1" e2="DDI-PubMed.25975423.s5.e2" /></sentence><sentence text=" Telaprevir did not affect etravirine pharmacokinetics, but increased rilpivirine Cmin, Cmax, and AUC by 93%, 49%, and 78%, respectively"><entity charOffset="1-11" id="DDI-PubMed.25975423.s6.e0" text="Telaprevir" /><entity charOffset="27-37" id="DDI-PubMed.25975423.s6.e1" text="etravirine" /><entity charOffset="70-81" id="DDI-PubMed.25975423.s6.e2" text="rilpivirine" /><pair ddi="false" e1="DDI-PubMed.25975423.s6.e0" e2="DDI-PubMed.25975423.s6.e0" /><pair ddi="false" e1="DDI-PubMed.25975423.s6.e0" e2="DDI-PubMed.25975423.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25975423.s6.e0" e2="DDI-PubMed.25975423.s6.e2" /><pair ddi="false" e1="DDI-PubMed.25975423.s6.e1" e2="DDI-PubMed.25975423.s6.e1" /><pair ddi="false" e1="DDI-PubMed.25975423.s6.e1" e2="DDI-PubMed.25975423.s6.e2" /></sentence><sentence text=" Both combinations were generally well tolerated" /><sentence text=" The small decrease in telaprevir exposure when coadministered with etravirine is unlikely to be clinically relevant"><entity charOffset="23-33" id="DDI-PubMed.25975423.s8.e0" text="telaprevir" /><entity charOffset="68-78" id="DDI-PubMed.25975423.s8.e1" text="etravirine" /><pair ddi="false" e1="DDI-PubMed.25975423.s8.e0" e2="DDI-PubMed.25975423.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25975423.s8.e0" e2="DDI-PubMed.25975423.s8.e1" /></sentence><sentence text=" The interaction between telaprevir and rilpivirine is not likely to be clinically relevant under most circumstances"><entity charOffset="25-35" id="DDI-PubMed.25975423.s9.e0" text="telaprevir" /><entity charOffset="40-51" id="DDI-PubMed.25975423.s9.e1" text="rilpivirine" /><pair ddi="false" e1="DDI-PubMed.25975423.s9.e0" e2="DDI-PubMed.25975423.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25975423.s9.e0" e2="DDI-PubMed.25975423.s9.e1" /></sentence><sentence text=" No dose adjustments are deemed necessary when they are coadministered" /><sentence text=" " /></document>